One of today's notable stocks on the rise is Progenics Pharmaceuticals (NASDAQ:PGNX), up 1.7% to $9.91. The S&P is trading higher by 0.3% to 1,317 and the Dow is trading 0.3% higher to 12,686.
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.
Progenics Pharmaceuticals has overhead space with shares priced $9.91, or 7.0% below the average consensus analyst price target of $10.67. The stock should find initial support at its 50-day moving average (MA) of $7.84 and further support at its 200-day MA of $6.99.
Over the past year, Progenics Pharmaceuticals has traded in a range of $4.50 to $9.94 and is now at $9.91, 120% above that low. The 200-day and 50-day moving averages have moved 0.58% higher and 2.66% higher over the past week, respectively.
